| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
National Institute on Drug Abuse (NIDA) |
| Information provided by: | National Institute on Drug Abuse (NIDA) |
| ClinicalTrials.gov Identifier: | NCT00000205 |
Purpose
The purpose of this study is to compare the efficacy of buprenorphine versus methadone.
| Condition | Intervention | Phase |
|
Opioid-Related Disorders |
Drug: Buprenorphine |
Phase III |
| ChemIDplus related topics: | Buprenorphine Buprenorphine hydrochloride |
| Study Type: | Interventional |
| Study Design: | Treatment, Double-Blind, Placebo Control |
| Official Title: | Buprenorphine Maintenance Protocol |
Eligibility
| Ages Eligible for Study: | 21 Years to 50 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
M/F ages 21-50. Opiate dependence according to DSM-IV criteria. Self-reported use within the last 30 days. Agreeable to conditions of study and signed informed consent.
Exclusion Criteria:
Psychiatric disorder that requires medication therapy. History of seizures. Pregnant and /or nursing women. Dependence on ETOH or benzodiazepines or other sedative/hynotics. Acute hepatitis. Other medical conditions that deem participation to be unsafe
Contacts and Locations| United States, California | |||||
| Friends Research Institute | |||||
| Los Angeles, California, United States, 90025 | |||||
| Principal Investigator: | Walter Ling, M.D. | Friends Research Institute, Inc. |
More Information
| Study ID Numbers: | NIDA-06082-1, R18-06082-1 |
| First Received: | September 20, 1999 |
| Last Updated: | November 3, 2005 |
| ClinicalTrials.gov Identifier: | NCT00000205 |
| Health Authority: | United States: Federal Government |
|
|
|
|
